米非司酮对酒精依赖者认知与抑郁的双盲安慰剂对照试验
本研究为2期双盲随机安慰剂对照试验,计划招募120名男性酒精依赖者,实际仅27人入组、21人有数据。米非司酮组14人、安慰剂组13人,评估停药4周后认知功能与抑郁症状。因样本量过小,无法得出米非司酮疗效结论,需更大规模试验。
要点
- 米非司酮为II型糖皮质激素受体拮抗剂,拟用于酒精脱毒后认知缺陷与抑郁症状。
- 因住院照护模式变化导致招募困难,最终仅27人入组、21人有可用数据。
- 样本量过小,无法就米非司酮疗效得出结论,需开展更大规模试验。
核心结论
- 因实际入组样本量远低于计划,无法就米非司酮对酒精依赖者认知与抑郁的疗效得出结论。
- 研究者认为需要更大规模的试验才能评估米非司酮的疗效。
研究设计与样本
- 2期治疗性双盲随机安慰剂对照临床试验,比较米非司酮与无效安慰剂。
- 计划招募120名符合纳入标准的参与者:男性、年龄18-60岁(含)、酒精依赖5年及以上。
- 随机分配至米非司酮组或等量安慰剂片组,疗程14天。
- 最终仅27人入组,21人有可用数据;米非司酮组14人,安慰剂组13人。
关键数值与推荐
- 米非司酮给药方案:前7天每日600 mg(早、午、晚各200 mg),后7天每日400 mg(早、晚各200 mg)。
- 主要结局为随机化后4周时的认知功能(CANTAB测量)与抑郁症状(BDI测量)。
- 试验注册号:ISRCTN54001953,注册日期2011年9月29日。
局限性
- 因酒精依赖住院照护服务发生显著变化,导致招募困难,实际样本量远低于计划。
- 样本量过小,无法对米非司酮的疗效作出可靠推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alcohol dependence is a significant issue contributing to disease burden. Changes in cortisol concentrations during alcohol withdrawal are associated with cognitive deficits and symptoms of depression. Current treatments are only successful for a small proportion of people and do not target cognitive deficits and symptoms of depression experienced by those who are alcohol dependent. The aim of this research is to determine the potential efficacy of mifepristone, a type II glucocorticoid receptor antagonist, to prevent symptoms of depression and cognitive deficits following alcohol detoxification. METHODS: This was a phase 2 therapeutic use trial. It was a double-blind randomised controlled clinical trial of mifepristone versus inactive placebo treatment. The trial aimed to recruit 120 participants who met the inclusion criteria: (1) male, (2) aged 18-60 years inclusive, and (3) alcohol dependent for 5 or more years. Participants were randomised to 600 mg a day mifepristone (200 mg morning, afternoon, and evening) for 7 days and 400 mg for the subsequent 7 days (200 mg morning and evening) or the equivalent number of placebo tablets for 14 days. Primary outcome measures were cognitive function (measured using the Cambridge Neuropsychological Test Automated Battery (CANTAB)) and symptoms of depression (measured using the Beck Depression Inventory (BDI)) at 4 weeks post-randomisation. RESULTS: Difficulties recruiting participants due to significant changes in the provision of inpatient care for alcohol dependence resulted in only 27 participants recruited to the trial, with data available for 21 participants. Fourteen participants were randomised to receive mifepristone and 13 to receive placebo. CONCLUSION: Larger trials would be needed to draw conclusions about the efficacy of mifepristone. TRIAL REGISTRATION: ISRCTN registry ISRCTN54001953 . Registered on 29 September 2011.
引用
- Donoghue K, Rose A, Coulton S, et al. Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence. Trials. 2020. PMID: 32938477. doi:10.1186/s13063-020-04726-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。